Analyst: Biden's insulin message won't negatively impact Novo Nordisk

The debate about prescription drug prices in the US is far from new, says Sydbank Analyst Søren Løntoft Hansen, pointing out that past years’ discounts on insulins haven’t stopped Novo Nordisk from booking record-breaking results.
Photo: Novo Nordisk / PR
Photo: Novo Nordisk / PR
by marketwire, translated by daniel pedersen

On Tuesday, President of the United States Joe Biden announced in his State of the Union Address that he would lower the cost of prescription drugs in the US.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading